Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $177.00.

Several research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday. Robert W. Baird boosted their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research note on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the sale, the executive vice president now owns 33,048 shares in the company, valued at $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 6,753 shares of company stock valued at $816,289. Insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. LSV Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 4.2% during the second quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company’s stock worth $264,750,000 after purchasing an additional 99,705 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 15.3% in the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Baupost Group LLC MA boosted its position in shares of Jazz Pharmaceuticals by 52.8% in the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after purchasing an additional 440,552 shares during the period. Dimensional Fund Advisors LP grew its stake in Jazz Pharmaceuticals by 48.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock worth $130,447,000 after buying an additional 398,549 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after buying an additional 48,708 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $123.04 on Monday. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $7.44 billion, a P/E ratio of 17.33, a P/E/G ratio of 1.02 and a beta of 0.57. The firm’s 50 day moving average price is $117.39 and its 200-day moving average price is $112.22. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.